NetworkNewsBreaks – Delic Holdings Inc. (CSE: DE
Post# of 135
(Total Views: 197)
Posted On: 03/31/2022 3:13:07 PM
NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces New Clinic Openings as Company’s Expansion Accelerates
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option at three of its ketamine centers; the spray is intended to treat adults with treatment-resistant depression and depressive symptoms of major depressive disorder. In addition, the the company’s Delic Labs received Health Canada 56 exemptions to perform research and development work for several substances, including MDMA, LSD, DMT, mescaline and 2C-B as well as to receive 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. Finally, the company announced the results of its first-ever survey on U.S. attitudes towards psychedelics. Conducted by the Harris Poll, the survey indicated that a majority of Americans who suffer from anxiety, depression, or PTSD feel that psychedelic medicine, including ketamine, psilocybin and MDMA, should be available. “Based on our survey results, the majority of affected Americans believe that psychedelic medicine should be made available to patients with treatment-resistant anxiety, depression or PTSD,” said Delic Holdings cofounder and CEO Matt Stang in the press release. “Our mission to make these new, science-backed medicines accessible and affordable to a greater number of people suffering from these conditions is more urgent than ever. The opening of the KWC Salt Lake City and Reno locations and the addition of FDA-approved SPRAVATO as a treatment option means we can serve more patients than any other ketamine provider in the U.S. With its latest Health Canada 56 exemptions, Delic Labs continues to lead the industry on the research of these novel psychedelic compounds and development of IP for future commercialization. Delic is opening doors to a future with more effective medicines for a variety of mental health conditions with longer lasting benefits and less side effects.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option at three of its ketamine centers; the spray is intended to treat adults with treatment-resistant depression and depressive symptoms of major depressive disorder. In addition, the the company’s Delic Labs received Health Canada 56 exemptions to perform research and development work for several substances, including MDMA, LSD, DMT, mescaline and 2C-B as well as to receive 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. Finally, the company announced the results of its first-ever survey on U.S. attitudes towards psychedelics. Conducted by the Harris Poll, the survey indicated that a majority of Americans who suffer from anxiety, depression, or PTSD feel that psychedelic medicine, including ketamine, psilocybin and MDMA, should be available. “Based on our survey results, the majority of affected Americans believe that psychedelic medicine should be made available to patients with treatment-resistant anxiety, depression or PTSD,” said Delic Holdings cofounder and CEO Matt Stang in the press release. “Our mission to make these new, science-backed medicines accessible and affordable to a greater number of people suffering from these conditions is more urgent than ever. The opening of the KWC Salt Lake City and Reno locations and the addition of FDA-approved SPRAVATO as a treatment option means we can serve more patients than any other ketamine provider in the U.S. With its latest Health Canada 56 exemptions, Delic Labs continues to lead the industry on the research of these novel psychedelic compounds and development of IP for future commercialization. Delic is opening doors to a future with more effective medicines for a variety of mental health conditions with longer lasting benefits and less side effects.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)